UPDATE 1-Abbott says its payoff from Mylan deal surged
April 22, 2015 at 12:09 PM EDT
April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.